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Abstract 
Epithelial ovarian cancer (EOC) is one of the deadliest common cancers. The five most 
common types of disease are high-grade and low-grade serous, endometrioid, mucinous and 
clear–cell carcinoma. Each of these subtypes presents distinct molecular pathogeneses and 
sensitivities to treatments. Recent studies show that certain genetic variants confer 
susceptibility to all subtypes whilst other variants are subtype-specific. Here we perform an 
extensive analysis of the genetic architecture of EOC subtypes. To this end, we used data of 
10,014 invasive EOC patients and 21,233 controls from the Ovarian Cancer Association 
Consortium genotyped in the iCOGS array (211,155 SNPs). We estimate the array heritability 
(attributable to variants tagged on arrays) of each subtype and their genetic correlations. We 
also look for genetic overlaps with factors such as obesity, smoking behaviours, diabetes, age 
at menarche, and height. We estimated the array heritabilities of high-grade serous disease 
(h2g= 8.8 ± 1.1%), endometrioid (h2g= 3.2 ± 1.6%), clear-cell (h2g = 6.7 ± 3.3%) and all EOC (h2g= 
5.6 ± 0.6%). Known associated loci contributed approximately 40% of the total array 
heritability for each subtype. The contribution of each chromosome to the total heritability 
was not proportional to chromosome size. Through bivariate and cross-trait LD score 
regression, we found evidence of shared genetic backgrounds between the three high-grade 
subtypes: serous, endometrioid and undifferentiated. Finally, we found significant genetic 
correlations of all EOC with diabetes and obesity using a polygenic prediction approach. 
 
  
Introduction 
 
In developed countries, epithelial ovarian cancer (EOC) is the leading gynaecological 
malignancy with an estimated annual incidence rate of 12 per 100,000 and a poor 5 year 
survival between 20% and 50% (Chornokur et al. 2015; Sopik et al. 2015; Sung et al. 2014). 
About 90% of invasive tumours in the ovary are of epithelial origin (Kurman R 2014). These 
tumours are divided into various histological subtypes that include: serous, mucinous, 
endometrioid, clear cell, Brenner, other minor types, as well as undifferentiated, mixed and 
unclassified carcinomas (Prat 2012; Sung et al. 2014). Serous carcinomas can be subdivided 
into high-grade (90%) and low-grade disease (10%) (Kurman and Shih Ie 2008; Malpica et al. 
2004; Shih Ie and Kurman 2004).  
Each epithelial ovarian cancer histologic subtype exhibits a distinct etiologic and molecular 
pathogenesis and sensitivity to treatment (e.g., chemotherapeutic agents) (Anglesio et al. 
2013; Della Pepa et al. 2015; Risch et al. 1996; Shih Ie and Kurman 2004; Soslow 2008). It has 
been suggested that serous carcinomas arise from the epithelial mucosal lining of the 
fallopian tube fimbriae or from endosalpingiotic deposits on the ovarian or peritoneal 
surfaces.  Clear-cell and endometrioid subtypes may arise from endometriotic lesions 
(Kurman R 2014; Wiegand et al. 2010), while mucinous tumours do not yet have a clear origin, 
though metaplastic transformation of the epithelial lining of ovarian inclusion cysts has been 
suggested. Serous carcinoma is by far the most deadly type of EOC, with 5-year survival of 
less than 20% for patients suffering from high-grade disease and 50% for those with low-grade 
disease (Malpica et al. 2004). In contrast, women with mucinous, endometrioid or clear-cell 
carcinomas tend to have better prognosis, with estimated 5-year survivals of 50%-60% 
(Malpica et al. 2004; Simons et al. 2015). These differences in survival are due at least in part 
to the fact that high-grade serous carcinomas are usually detected at advanced stages of 
disease but the other subtypes at earlier stages (Devouassoux-Shisheboran and Genestie 
2015; Malpica et al. 2004; Simons et al. 2015). 
Genetic studies have shown that around 20% of patients with high-grade serous cancers carry 
germ-line and somatic mutations in BRCA1 or BRCA2 (Alsop et al. 2012; Berchuck et al. 1998) 
along with somatic mutations in TP53 that are present in most tumours (Cancer Genome Atlas 
Research 2011).  Alterations in KRAS and BRAF but not TP53 have been associated with low-
grade serous carcinomas (Della Pepa et al. 2015; Grisham et al. 2013; Jones et al. 2012). 
Mucinous carcinomas also frequently have somatic mutations in KRAS (Cuatrecasas et al. 
1997) in addition to mutations in HER2 (Anglesio et al. 2013). Endometrioid and clear cell 
carcinomas often carry somatic mutations in AR1D1A and PIK3CA (Jones et al. 2010). In 
addition, genome-wide association studies (GWAS) have found 20 common polymorphisms 
associated with risk of EOC (Bojesen et al. 2013; Bolton et al. 2010; Goode et al. 2010; 
Permuth-Wey et al. 2013; Pharoah et al. 2013; Song et al. 2009). 
Specific germ-line SNPs are commonly found in the different EOC subtypes. However, these 
variants explain only a fraction of the cases, thus it is not known whether or not other genetic 
components are shared among the subtypes. One of our previous studies (Lu et al. 2015) 
estimated the array heritability (i.e., heritability explained by about 200,000 genotyped SNPs 
but not all the genome) of all EOC to be 5.6%, and 8.8% for the most common EOC subtype, 
high-grade serous. 
Beside genetic factors predisposing to these diseases, some environmental factors such as 
smoking (Collaborative Group on Epidemiological Studies of Ovarian et al. 2012; Faber et al. 
2013) and obesity (Aune et al. 2015; Collaborative Group on Epidemiological Studies of 
Ovarian 2012; Olsen et al. 2013) may be associated with increases in risk of some subtypes of 
EOC. In addition, traits including achieved height (Aune et al. 2015; Wiren et al. 2014) and 
diabetes mellitus (Gapstur et al. 2012; Lee et al. 2013) have been positively associated to EOC. 
In contrast, some studies have shown that age at menarche (Gong et al. 2013) is inversely 
associated with risk of EOC. Evidence suggests that all these traits have heritable components. 
Genetic variation may explain as much as 80% of the total variance of height (Yang et al. 2010) 
or even 40% for smoking behaviour (Vink and Boomsma 2011; Vink et al. 2005). It is possible 
that part of the heritability of EOC may be explained by the heritability of these traits, if they 
are associated with EOC risk. 
In this work, we investigate three aspects of the genetic architecture of EOC and its subtypes: 
(i) the total genetic contribution of all array-genotyped SNPs (genome-wide, per chromosome 
and after accounting for known EOC associated loci); (ii) the genetic correlations between 
EOC subtypes; and (iii) the genetic correlations between EOC subtypes and risk factors such 
as obesity and smoking. To this end, we use genotype and risk-factor data from studies 
participating in the Ovarian Cancer Association Consortium (OCAC). We quantify genetic 
contributions to disease using genome-wide complex trait analysis (GCTA) (Lee et al. 2011; 
Yang et al. 2010; Yang et al. 2011a). Then, we evaluate shared genetic backgrounds between 
EOC subtypes and candidate risk factors using complementary approaches: bivariate linear 
mixed models (Lee et al. 2012), cross-trait LD score regression (Bulik-Sullivan et al. 2015a) and 
polygenic risk prediction (International Schizophrenia et al. 2009). 
Methods 
 
Data 
We used data from the Ovarian Cancer Association Consortium (OCAC). This dataset consists 
of custom Illumina iCOGS array genotyping of 47,630 cases and controls in 43 OCAC studies. 
Detailed description of the content of the array can be found elsewhere (Pharoah et al. 2013). 
In brief, the array consists of 211,155 variants within breast, ovarian and prostate cancer 
susceptibility loci as well as candidate SNPs, SNPs associated with other cancers and SNPs 
associated with relevant quantitative traits such as body mass index (BMI) and the onset of 
menarche. 
 We applied standard quality control (QC) for the genotype data. First, we selected only 
samples from European ancestry studies and that were within 6 s.d. from the genotype-
derived PC1 and PC2 from the 1000 Genomes European population [Supplementary Figure 
1]. We excluded individuals with missing genotypes in 5% or more of the SNPs. Likewise, we 
removed SNPs with call rates below 99%, minor allele frequencies (MAF) below 1% and SNPs 
that deviated from Hardy-Weinberg equilibrium at P<0.0001 (Lu et al. 2014). Further, given 
that our analytic methods are sensitive to relatedness (e.g., results may be biased by common 
environmental factors in relatives) we removed individuals such that no sample pairs had 
identity by descent (IBD) > 10% (i.e., less than second cousins), giving more priority to keeping 
cases than controls. In concordance with one of our previous work (Lu et al. 2015), we focused 
only on those with invasive EOC tumours. In total, 10,014 EOC cases and 21,233 controls met 
these criteria and were genotyped for 195,183 SNPs. The number of cases according to 
histologic subtype are displayed in Table 1. The numbers of initial cases and controls per study 
are summarized in Supplementary Table 1. 
 
Analysis  
We estimated the variance explained by all SNPs in the array (h2g) (Lee et al. 2011), the 
variance after removing known loci, and the variance explained by each chromosome for each 
of the EOC subtypes. We used GCTA to calculate one genetic relationship matrix (GRM) for all 
autosomes.  
The estimated variance explained was transformed from the observed scale to an unobserved 
continuous “liability” scale using a probit transformation (Lee et al. 2011) taking into account 
the disease prevalence. The lifetime risk of the various EOC subtypes were calculated as the 
lifetime risk of ovarian cancer (~1% according to the Surveillance, Epidemiology and End 
Results (SEER),   http://seer.cancer.gov/statfacts) multiplied by the relative proportion of 
each subtype according to SEER program DevCan database 
(http://surveillance.cancer.gov/devcan/canques.html) in all ovarian cancer. Given that 
around 90% of ovarian cancers are of epithelial origin, we used 0.9% as the prevalence for all 
EOC. As h2g, is derived solely from the SNPs tagged on the genotyping array instead of the 
whole genome, it provides a lower bound on heritability estimates (Lu et al. 2014). 
Phenotypes were modeled as a linear function of the sum of the additive effects due to all 
SNPs associated with trait-associated variants and residual effects. Variance components 
were estimated using residual maximum likelihood (REML) (Yang et al. 2010). For tests of 
whether a variance component is zero or not, the test is one-sided and under the null 
hypothesis that the test statistic follows a 50:50 mixture of a point mass at zero and the χ1 
distribution (Yang et al. 2010; Yang et al. 2011a). One sided p-values were calculated to 
estimate statistical significance. Likewise, To estimate the proportion of h2g that is explained 
by the known loci (WNT4, RSPO1, SYNPO2, GPX6, ABO, ATAD5, C19orf62, CMYC, TIPARP, 
BNC2, ARHGAP27, TERT, RAD51B/C/D, BRIP1, BARD1, PALB2, NDN, CHMP4C, MLLT10, HNF1B, 
BRCA1, BRCA2, KRAS, TP53, HER2, AR1D1A and PIK3CA (Bojesen et al. 2013; Bolton et al. 2010; 
Goode et al. 2010; Permuth-Wey et al. 2013; Pharoah et al. 2013; Song et al. 2009)), we re-
computed the GRM with the SNPs (6,391 SNPs) close to the known loci SNPs (+/- 1 megabase 
either side) removed. 
 
Similarly, in order to investigate the genetic contributions within of each of the chromosomes, 
we computed one GRM per chromosome and performed analyses using REML fitting the 22 
genetic variance components in the model as implemented in GCTA with the flag –mgrm 
(multiple GRMs) (Yang et al. 2011b). Given that loading 22 GRMs with the 21,051 controls and 
the cases of the various histotypes was computationally intractable, we assigned to each case 
just one control of the same study, yielding smaller GRMs (e.g., for high-grade Serous cancer 
there were 3,705 cases and 3,705 controls). We then normalized the contribution of each 
chromosome by the number of independent SNPs (percentage) in the iCOGs array per 
chromosome. This number of independent SNPs was estimated through LD pruning using the 
PLINK command –indep 50 5 1.2, where 50 is the window size (#SNPs), 5 is the number of 
SNPs the window can shift, and 1.2 is 1/(1-R2), where R2 is the multiple correlation coefficient 
for a SNP regressed on all other SNPs simultaneously (Chang et al. 2015). In order to 
approximate the s.e. of the variance explained by each chromosome, we performed a 
jackknifing procedure up to 1000 times, taking 80% of the cases and 80% of the controls each 
time. Given the complexity of the sample, around 20% of the jackknifing repetitions did not 
converge within 1000 iterations so the standard errors were computed from just the 800 
successful jackknifings. 
 
To investigate the genetic correlations between the subtypes, in order to remove potential 
biases from overlapping control samples from the different studies, we matched each case to 
1 control of the same study, and distributed controls in such a way that each EOC subtype had 
separate sets of controls. For example, all of the controls for mucinous EOC were different 
from the endometrioid EOC controls. 
 
Genetic correlation (rg) represents the proportion of the total genetic variance that two traits 
share. In order to investigate the rg between EOC subtypes, we used two distinct approaches 
that can be applied to population-based samples. We first used the GRM in a bivariate mixed-
effects linear model implemented in GCTA (Cross-Disorder Group of the Psychiatric Genomics 
et al. 2013) to compute the genetic correlations between the various EOC subtypes. The 
estimated genetic correlation is the additive genetic covariance between traits, normalized 
by the geometric mean of the individual trait genetic variances (producing values from -1 to 
+1). The additive genetic covariance was estimated by relating trait covariances between 
unrelated individuals to genetic relationship estimates from marker data. Increased 
covariance between traits with high genetic relationship values implies a positive genetic 
correlation between traits. In order to control for any potential effects of population 
stratification, all the analyses were performed using the first 10 principal components (PCs) 
of the genotypes as covariates. Estimates are reported as genetic correlation ± standard error. 
 We also used cross-trait LD score regression (Bulik-Sullivan et al. 2015a), a recently developed 
approach that is able to estimate genetic correlations using solely GWAS summary statistics 
and is not affected by sample overlap. We first ran genome-wide association analyses using 
the same samples as when computing h2g per each EOC subtype (i.e., we repeatedly made 
use of all of the controls for analysis of each subtype) and with the 10 first PCs and study site 
as covariates. Genomic inflation factors for these GWAS analyses ranged from 0.99 for 
mucinous cancer to 1.07 for all EOC. We used the LD-scores estimated by Bulik-Sullivan, et 
al.(Bulik-Sullivan et al. 2015a; Bulik-Sullivan et al. 2015b) available at 
http://www.broadinstitute.org/~bulik/eur_ldscores/ which are based on the 1000 Genomes 
European population and estimated within 1-cM windows.  We then estimated the genetic 
correlation using software available at https://github.com/bulik/ldsc with the default 
parameters. 
 
Genetic correlations between EOC subtypes and risk factors 
Using cross-trait LD score regression, we estimated genetic correlations between risk factors 
and EOC histotypes. To this end, we used publicly available GWAS summary results from the 
latest GWAS meta-analyses of BMI and height from the Genetic Investigation of 
Anthropometric Traits (GIANT) consortium. These analyses included 339,225 (Locke et al. 
2015) and 253,288 (Wood et al. 2014) individuals, respectively. We also estimated genetic 
correlations using the GIANT extreme anthropometric traits GWAS which used obesity class 
1 (BMI>30), class 2 (BMI>35) and class 3 (BMI>40) groups as cases, and individuals with 
BMI<=25 as controls, in a sample of 263,407 individuals (Berndt et al. 2013). Genetic overlaps 
with age at menarche was carried out based on the GWAS of the Reproductive Genetics 
Consortium which involved 182,416 women (Perry et al. 2014). Smoking behaviour genetic 
predisposition was approximated based on the Tobacco and Genetics Consortium GWAS 
which involved 74,053 participants (Tobacco and Genetics 2010). Finally, for diabetes, we 
used the summary results for type 2 diabetes GWAS of the DIAGRAM (DIAbetes Genetics 
Replication And Meta-analysis) consortium, which involved 34,840 cases and 114,981 
controls (Morris et al. 2012). 
 
We also carried out a polygenic risk-prediction approach. This method involves the 
computation of polygenic risk scores (PGRS) of each of the risk factors and uses these scores 
to predict disease status (International Schizophrenia et al. 2009). The PGRS describes a 
predicted phenotypic value based on the genetic component and is computed by aggregating 
the magnitude of associations of many variants. These associations are estimated using a 
discovery set of subjects (e.g., for height or BMI) to identify relevant SNPs and estimate the 
magnitude of association of each, and these magnitudes or the number of “high-risk” alleles 
in each SNP are then summed to create a score. Subsequently, we examine the association of 
this score within a target subject set (e.g., EOC cases and controls). If the score association is 
significant, it implies a genetic correlation between the two traits. In this study, we selected 
variants to compute the PGRS based on 11 p-value thresholds (<0.00001, 0.001, 0.01, 0.05, 
0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1). Given the nature of the iCOGS array in which many loci have 
high densities of tagged SNPs, we performed linkage disequilibrium (LD) clumping in order to 
remove correlated variants (r2>0.2) within 500kb windows for each component of the PGRS. 
The computations for PGRS and LD clumping were performed with PLINK (Chang et al. 2015). 
Finally, we standardized each of the PGRS to have mean 0 and variance 1 and examined their 
associations with the various EOC subtypes through logistic regression, adjusted for the first 
10 PCs. 
 
Multiple testing correction 
The polygenic risk prediction approach carries a high multiple testing burden, as does 
consideration of the various histologic groups and risk factors. However, given that we 
computed 11 PGRS for each trait based on sequential p-value thresholds, our statistics are 
not independent. In order to estimate the real number of independent hypotheses, we 
computed the correlation matrix of all the PGRS used in this study and fed this into a Matrix 
Spectral Decomposition (matSpD) algorithm (Nyholt 2004), to estimate the number of 
independent variables. This algorithm provides an equivalent number of independent 
variables in a correlation matrix, by examining the ratio of the observed eigenvalue variance 
to its theoretical maximum. We estimated the number of independent PGRS to be 35 out of 
the 88 PGRS. As we examined these 35 independent PGRS in five separate EOC subtypes (high-
grade serous, endometrioid, clear cell, mucinous and unknown), our significance threshold 
for the polygenic risk prediction analyses was 0.05/(35*5)=.00029. 
 
Results 
 
Genetic contribution of each chromosome and known loci 
Fitting a GRM computed after removing known EOC-associated loci in univariate mixed-effect 
linear models implemented in GCTA (Yang et al. 2010; Yang et al. 2011a), we found that the 
known loci contributed about 40% of the total heritability of EOC and each of the subtypes 
[Table 1]. The estimated heritability of all EOC dropped from 5.6% to 3.6% once we removed 
known EOC-associated loci from the GRM. We observed a similar reduction of variance 
explained by the polygenic component for the EOC subtypes high-grade serous (8.8% to 
4.7%), endometrioid (3.2% to 2.0%) and clear cell (6.7% to 4.6%) [Table 1]. Interestingly, in 
contrast to grade 1 and grade 2 (G1/G2) endometrioid where the heritability did not drop 
substantially (4.4% to 3.7%), grade 3 (G3) endometrioid h2g dropped from 4.9% to 0.9%. As 
shown previously (Lu et al. 2015), the heritability of mucinous cancer was not detectably 
different from 0. We were unable to perform any analyses for low-grade serous cancer given 
the small sample size (Ncases=350). We also had a set of cases with unknown EOC subtype 
classification; we expect that a high portion of these are individuals with undifferentiated 
high-grade serous, endometrioid or mixed serous EOC subtypes. For these, the heritability 
dropped from 7.0% to 4.1% after removing known loci. 
 
In order to inspect the contributions of heritability per chromosome, we computed one GRM 
per chromosome, and fitted the multiple genetic variance components into linear mixed 
models as above. We found that the chromosomal contributions were not proportional to the 
number of independent SNPs in each of the chromosomes [Figure 1]. For example, the 
contribution of chromosomes 9, 11, 17 and 19 to high-grade serous EOC were larger than 
expected the 95% confidence interval (approximated through jackknifing 1000 times) did not 
overlap with 1. In contrast chromosomes 4, 10, 12, 14, 18 and 20 contributed less than 
expected. 
 
Genetic correlation between EOC subtypes 
We used the GRM as a random effect in a bivariate mixed-effects linear model implemented 
in GCTA to assess genetic heterogeneity across EOC histologic subtypes. Table 2 summarizes 
the genetic correlations between the various EOC subtypes. We found significant genetic 
overlap between high-grade serous EOC and endometrioid EOC (rg = 0.63 ± 0.27 ; P=.0029). 
Given that high-grade serous disease is not infrequently misclassified as endometrioid EOC 
(Gilks et al. 2008), we also estimated the genetic correlations separating (G1/G2) 
endometrioid disease from (G3). Here we found that the genetic correlation between high-
grade serous and G1/G2 endometrioid cancer was lower (rg = 0.33 ± 0.23; P=.062) than 
between G3 endometrioid and high-grade serous cancer (rg = 1.00 ± 0.83; P=.00078), 
suggesting that potential misclassification may have inflated the genetic correlation estimate 
when using all endometrioid EOC. Interestingly, we observed an appreciable but non-
significant genetic overlap of about rg = 0.5 between low-grade endometrioid and clear-cell 
EOC. We also found that the genetic correlations between “unknown/unclassified” EOC and 
high-grade serous and high-grade endometrioid disease were significant and essentially 1 (rg 
= 1.0 ± 0.30; P=10−7 and rg = 1.0 ± 0.96 P=.0049, respectively). The REML bivariate analyses 
involving Mucinous did not converge so did not yield any meaningful estimates. Further, 
removing known associated loci from the analyses affected the genetic correlation between 
endometrioid EOC (high and low grade) in a way that this was no longer significant [Table 2].  
 
Given that splitting the controls during the bivariate analyses to avoid sample overlap could 
have resulted in decreased power to detect genetic correlations; we complemented the 
genetic correlation analysis with the cross-trait LD score regression method, which is not 
biased by overlapping samples. In line with our results above, we found a statistically 
significant genetic correlation between high-grade serous EOC and endometrioid EOC (rg 
=0.67 ± 0.25; P=7.4E-03), high-grade serous EOC and unknown EOC (rg = 0.63 ± 0.25; P=.013) 
and endometrioid EOC and unknown EOC (rg =1.00 ± 0.30; P=5.7E-04) [Table 3].  
 
Genetic overlap of EOC subtypes and associated environmental factors 
In order to investigate the genetic overlap between all EOC and age at menarche, BMI, 
obesity, smoking, height and diabetes we used the cross-trait LD score regression method as 
well as a polygenic risk-prediction approach. We did not detect any significant genetic 
correlations using cross-trait LD score regression [Table 4]. However, through the polygenic 
risk prediction approach, we found significant genetic overlap (at Bonferroni P-value 
threshold = .00029) of all EOC with obesity and with diabetes [Table 5]. The genetic overlap 
with diabetes appeared mainly in association with mucinous EOC. Overall, the directions of 
association are consistent with what has been reported in observational studies (Aune et al. 
2015; Collaborative Group on Epidemiological Studies of Ovarian 2012; Faber et al. 2013; 
Olsen et al. 2013), although most of these associations are not significant. 
 
Discussion  
 
In this work, we have investigated the genetic architecture of EOC and its different subtypes. 
Our univariate analyses show an extent of hidden heritability inherent in the iCOGS array, 
with known associated loci accounting for about 40% of the total array heritability for most 
EOC histotypes, except for high-grade endometrioid, where they account for most of hg2. Is 
important to note that to reach these estimates we removed 2Mb per locus, which was done 
to ensure that no effect of these loci remained; however, this could also have inflated the 
estimates. We also showed that the hidden heritability is not spread proportionally across the 
chromosomes, with some contributing very little to the array heritability and others up to 5 
times more than expected given their iCOGS SNP compositions. A limitation in our univariate 
experiments was that it was underpowered to compute meaningful estimates for low-grade 
serous and mucinous EOC. Although we had a bigger sample size for mucinous EOC than clear 
cell EOC, the analyses could have been affected by how each individual study deal with mucin-
producing peritoneal tumours. 
 
Using bivariate linear mixed-model and cross-trait LD score-regression approaches, we 
investigated genetic correlations between the various EOC subtypes. The bivariate linear 
mixed model provides unbiased estimates of genetic correlation and it requires individual 
genotype data in order to compute the GRM. Cross-trait LD score regression only requires 
summary results from the discovery set, and in contrast to the bivariate mixed-model 
approach, it allows sample overlap (in this case, overlapping controls) (Bulik-Sullivan et al. 
2015a). Whilst studies have shown shared germ-line risk mutations across the various EOC 
subtypes, these account for only a small fraction of general heritability (Bojesen et al. 2013; 
Bolton et al. 2010; Goode et al. 2010; Permuth-Wey et al. 2013; Pharoah et al. 2013; Song et 
al. 2009). We found a very high genetic correlation between high-grade serous EOC and 
poorly differentiated (G3, high-grade) endometrioid disease, and with unknown/unclassified 
EOC, which represents undifferentiated epithelial carcinoma. These correlations seem 
entirely reasonable, because high-grade endometrioid disease is sometimes misdiagnosed as 
high-grade serous, or may constitute a version of high-grade serous with slightly different 
differentiation. Undifferentiated ovarian carcinoma clinically resembles high-grade serous in 
response to treatment and in mortality. Low-grade serous, low-grade endometrioid and clear-
cell carcinoma (which is relatively low grade) are heritability-distinct from the high-grade 
diseases and behave that way. Mucinous ovarian cancer seems to be a largely separate 
disease and has its own set of risk factors (Risch et al. 1996). It does not appear to be related 
heritably to the other ovarian cancer histotypes. 
 
We also considered whether the heritability of EOC and its subtypes could be explained (at 
least partly) via factors such as obesity, height, diabetes, smoking and age at menarche. As 
these factors have genetic components, it is plausible that the heritability of EOC could reflect 
the heritability of a causal factor. Using cross-trait LD score regression, we had insufficient 
power to detect genetic correlations, as this approach is greatly affected by small numbers of 
SNPs and by small sample sizes. However, through a polygenic risk prediction approach – 
which, although it does not directly quantify genetic overlap, is powerful for detecting genetic 
correlations between traits when the discovery and target sets are well powered (Dudbridge 
2013), we found a significant positive genetic overlap between diabetes, obesity and all EOC. 
This genetic overlap appeared to be concentrated within mucinous disease and may not 
reflect other EOC histotypes. Genetic correlation in this analysis is estimated based on a large 
number of SNPs, so it is possible that the correlations seen between diabetes and obesity and 
EOC may be mediated by an upstream phenotype (e.g. hormonal changes). Genetic overlap 
analyses between EOC and the other risk factors did not reveal any other significant 
associations. Potential reasons for this include small sample sizes for some of the EOC 
subtypes, and incomplete mapping of relevant variants of the risk factors (i.e., variants in the 
iCOGS array explain only a limited amount of variance of the risk factors). 
 
Is important to note that our results were derived from SNPs tagged in the iCOGS array. Hence 
the numbers of SNPs included in the analyses (195,183 SNPs) are smaller than in a typical 
GWAS array. Additional analyses could be performed on imputed genotypes from the iCOGS 
data; however, the iCOGS array is not designed to tag the whole genome, so imputation 
would likely still be limited to the existing tagged regions. Nevertheless, this array, which 
included several SNPs associated with other cancer types as well as with relevant quantitative 
traits such as BMI and the onset of menarche (Pharoah et al. 2013), allowed us to establish 
reasonably accurate estimates where the target sample sizes were well powered (e.g., high-
grade serous, endometrioid, unknown/undifferentiated, and all EOC). 
 
In summary, our results show that the major important EOC subtypes are genetically very 
homogeneous, and likely arise from a combination of known risk factors plus genetic 
contributions (beyond the known genetic predisposition mutations). This commonality 
highlights that high-grade disease could be considered a single clinical entity, with perhaps 
only minor variation between the serous, endometrioid and undifferentiated types. Low-
grade histotypes, as well as mucinous ovarian cancer, likely represent more distinct 
pathologic variation. We also found that a great proportion of heritability is “missing”. Our 
analyses will be complemented once data of individuals genotyped in the OncoArray, which 
integrates a GWAS backbone, becomes available. 
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 Table 1. Array heritabilities (h2g) and standard errors (s.e.) for invasive EOC according to histological 
subtype. Results for all iCOGS SNPs and after removing known associated loci. Disease prevalence of 
EOC subtypes is calculated as the lifetime risk of ovarian cancer multiplied by the relative proportion 
of the corresponding EOC subtype. See Methods section . Bolded estimates are statistically 
significantly different from 0. 
*Loci removed: WNT4, RSPO1, SYNPO2, GPX6, ABO, ATAD5, C19orf62, CMYC, TIPARP, BNC2, 
ARHGAP27, TERT, RAD51B/C/D, BRIP1, BARD1, PALB2, NDN, CHMP4C, MLLT10, HNF1B, BRCA1, 
BRCA2, KRAS, TP53, HER2, AR1D1A and PIK3CA. 
  
Subtype Cases Control
s 
Life-
time 
risk 
All SNPs Removing Known Loci* 
h2g s.e. P-
value 
h2g s.e. P-value 
High-grade Serous 4098 21233 0.005
5 
0.08
8 
0.01
0 
2.2E-
16 
0.04
7 
0.00
9 
1.83E-
09 
Clear cell 620 21233 0.000
5 
0.06
7 
0.03
3 
0.017 0.04
6 
0.02
9 
0.058 
Endometrioid (all) 1342 21233 0.001 0.03
2 
0.01
6 
0.016 0.02
0 
0.01
4 
0.077 
Endometrioid 
G1/G2 
906 21233 0.001 0.04
4 
0.02
4 
0.025 0.03
7 
0.02
1 
0.037 
Endometrioid G3 436 21233 0.001 0.04
9 
0.04
6 
0.127 0.00
9 
0.04
1 
0.417 
Mucinous 658 21233 0.000
5 
0.00
0 
0.02
8 
0.5 0.00
0 
0.02
5 
0.5 
Unknown 2934 21233 0.009 0.07
0 
0.01
5 
1.1E-
10 
0.04
1 
0.01
2 
1.1E-04 
All 1001
4 
21233 0.009 0.05
6 
0.00
6 
2.2E-
16 
0.03
6 
0.00
5 
2.2E-16 
 Table 2. Genetic correlations and (standard error) between major EOC subtypes as estimated from 
iCOGS array. Lower triangular matrix shows the genetic correlation using all the SNPs in the iCOGS 
array, while the upper triangular matrix shows the genetic correlation after removing known 
associated loci. For these calculations, each case was matched to one control in a way that none of 
the subtypes share any controls. Analyses for mucinous and low-grade serous EOC subtypes were 
underpowered to yield reliable estimates. 
 
Bolded estimates are significantly different from 0. 
* Significance (P-value) where the null hypothesis rG=1. 
 
 
 
 
  
Subtype  High-grade 
Serous  
Endometri
oid (all) 
Endometri
oid G1/G2 
Endometri
oid G3 
Clear Cell Unknown 
High-grade 
Serous 
- 0.48 (0.35) 
P=0.072 
0.24 (0.30) 
P=0.21 
1.0 (2.66) 
P=0.5 
0.29 (0.42) 
P=0.24 
1.0 (0.510) 
P=5.1E-04 
Endometrioid 
(all) 
0.63 (0.27) 
P=0.0029 
- - - 0.73 (0.64) 
P=0.088 
0.50 (0.47) 
P=0.12 
Endometrioid 
G1/G2 
0.33 (0.23) 
P=0.062 
- - 0.36 (1.25) 
P=0.30* 
0.42 (0.53) 
P=0.20 
0.37 (0.41) 
P=0.18 
Endometrioid G3 1.0 (0.83) 
P=7.8E-04 
- 0.42 (0.56) 
P=0.2* 
- 1.00 (1.68) 
P=0.5 
1.0 (4.44) 
P=0.5 
Clear Cell 0.28 (0.33) 
P=0.18 
0.69 (0.56) 
P=0.074 
0.52 (0.54) 
P=0.14 
0.99 (0.87) 
P=0.073 
- 0.09 (0.55) 
P=0.43 
Unknown 1.0 (0.30) 
P=1.0E-07 
0.68 (0.33) 
P=0.0082 
0.42 (0.29) 
P=0.057 
1.0 (0.96) 
P=0.0049 
0.15 (0.39) 
P=3.5E-01 
- 
Table 3. Cross-trait LD score regression between EOC subtypes. Estimates and (standard errors) are 
reported. Analyses for mucinous and low-grade serous EOC subtypes were underpowered to yield 
reliable estimates. 
  HG Serous Endometrioid Endometrioid 
G1/G2 
Endometrioid 
G3 
Clear Cell Unknown 
HG Serous - 0.82 (0.49) 
P=0.095 
0.35 (0.41) 
P=0.41 
1.0 (1.17) 
P=0.20 
- 0.46 (0.46) 
P=0.31 
Endometrioid 0.67 (0.25) 
P=0.0074 
- - - - 1.0 (0.41) 
P=0.01 
Endometrioid 
G1/G2 
0.35 (0.25) 
P=0.15 
- - 0.49 (0.70) 
P=0.47* 
- 0.85 (0.40) 
P=0.035 
Endometrioid 
G3 
1.0 (0.79) 
P=0.15 
- 0.53 (0.67) 
P=0.48* 
- - 1.0 (0.73) 
P=0.15 
Clear Cell 0.53 (0.57) 
P=0.35 
0.91 (0.80) 
P=0.26 
0.71 (0.59) 
P=0.23 
1.00 (1.06) 
P=0.29 
- - 
 
Unknown 0.63 (0.25) 
P=1.3E-02 
1.0 (0.30) 
P=5.7E-04 
0.77 (0.33) 
P=0.02 
1.00 (0.79) 
P=0.14 
0.38 (0.53) 
P=0.47 
- 
Bolded estimates are significantly different from 0. 
 
Table 4. Genetic correlation between risk factors and EOC subtypes using cross-trait LD score 
regression. Estimates and (standard errors) are reported. Analyses for mucinous and low-grade 
serous EOC subtypes were underpowered to yield reliable estimates. 
  All HG Serous Endometrioid Clear Cell Unknown 
BMI 0.045 (0.07) 
P=0.52 
-0.04 (0.08) 
P=0.63 
0.18 (0.11) 
P=0.10 
-0.01 (0.16) 
P=0.96 
0.07 (0.08) 
P=0.38 
Smoking -0.34 (0.29) 
P=0.23 
-0.43 (0.33) 
P=0.20 
-0.37 (0.43) 
P=0.39 
-0.44 (0.66) 
P=0.51 
-0.17 (0.31) 
P=0.58 
Height 0.081 (0.062) 
P=0.19 
0.13 (0.09) 
P=0.15 
0.03 (0.09) 
P=0.69 
0.24 (0.17) 
P=0.17 
0.00 (0.08) 
P=0.98 
Menarche -0.07 (0.08) 
P=0.38 
-0.23 (0.13) 
P=0.06 
-0.04 (0.12) 
P=0.75 
0.32 (0.36) 
P=0.36 
0.05 (0.09) 
P=0.59 
Obesity* 
>30 BMI 
0.05 (0.09) 
P=0.58 
-0.02 (0.09) 
P=0.86 
0.26 (0.17) 
P=0.13 
-0.18 (0.26) 
P=0.50 
0.12 (0.11) 
P=0.27 
Obesity* 
>35 BMI 
0.019 (0.087) 
P=0.83 
-0.03 (0.11) 
P=0.80 
0.02 (0.18) 
P=0.90 
-0.23 (0.37) 
P=0.54 
0.17 (0.12) 
P=0.17 
Obesity* 
>40 BMI  
 
-0.02 (0.15) 
P=0.88 
-0.02 (0.17) 
P=0.92 
-0.06 (0.30) 
P=0.84 
NA 0.03 (0.19) 
P=0.89 
Diabetes 0.04 (0.12) 
P=0.75 
-0.04 (0.14) 
P=0.74 
0.04 (0.19) 
P=0.84 
-0.29 (0.38) 
P=0.45 
0.21 (0.14) 
P=0.15 
*Reference group was individuals with BMI <=25  
 
Table 5. Odds Ratios corresponding to 1 standard deviation increase in the PGRS and significance 
estimates (P-values) from the polygenic risk prediction approach between “environmental factors” 
PGRS and EOC subtypes. The displayed numbers correspond to the best association p-value out of 
the 11 different PGRS which were derived using different p-value thresholds. In this part we used the 
total set of controls with each of the EOC subtypes. 
 
HG Serous  Mucinous Clear Cell Endometrioi
d 
Unknow
n  
ALL 
Menarche 0.99 (0.54) 1.09 (0.036) 1.05 (0.2) 1.04 (0.12) 1.04 
(0.086) 
1.02 (0.17) 
BMI 1.04 
(0.028) 
1.05 (0.26) 1.06 (0.17) 1.07 (0.011) 1.04 
(0.068) 
1.04 (0.003) 
Smoking 1.03 (0.11) 0.93 (0.067) 0.92 
(0.049) 
1.04 (0.18) 0.95 
(0.0071) 
0.97 (0.019) 
Height 1.03 (0.14) 1.1 (0.015) 1.1 (0.025) 1.04 (0.17) 0.96 
(0.06) 
1.03 (0.022) 
Diabetes 1.04 
(0.021) 
1.18 (1.1e-
05) 
1.08 
(0.067) 
1.07 (0.011) 1.04 
(0.034) 
1.05 (4.1e-
04) 
Obesity 
>30BMI 
1.05 
(0.0051) 
1.06 (0.15) 1.06 (0.14) 1.04 (0.19) 1.04 
(0.032) 
1.05 (2.6e-
04) 
Obesity 
>35BMI 
1.03 (0.08) 1.05 (0.21) 0.9 (0.012) 1.02 (0.42) 1.05 
(0.028) 
1.04 
(0.0053) 
Obesity 
>40BMI 
1.03 (0.15) 1.06 (0.14) 0.87 
(0.0015) 
0.96 (0.13) 1.03 
(0.19) 
0.98 (0.21) 
Bolded estimates are statistically significant (Bonferroni P-value threshold 2.9x10-4). 
*Reference group was individuals with BMI <=25  
 
  
Figure 1. Contribution to the heritability by chromosome versus expected. Black vertical 
lines show the 95% confidence intervals approximated through jackknifing up to 1000 times. 
These are only shown for those instances that do not overlap with 1 to facilitate 
visualization. The same graph with all confidence intervals is included as supplementary 
figure 2.  
  
  
  
Supplementary Material: Assessing the Genetic Architecture 
of Epithelial Ovarian Cancer Histological Subtypes. 
 
 
 
Supplementary Figure 1. Genotype principal component analysis of OCAC samples and 1000 
Genomes. X and Y axes display the number of standard deviations from 1000 Genomes EUR 
populations. Dotted lines enclose the samples used in this study.
Study Name Country 
 
Code Controls Serous Mucinous Endometrioid Clear 
Cell 
HG 
Serous 
Other All 
invasive 
Australian Cancer Study  Australia ACS 175 104 7 22 9 89 32 166 
Australian Ovarian Cancer Sutidy Australia AOC 802 448 35 84 43 409 118 714 
Bavarian Ovarian Cancer Cases and Controls Germany BAV 142 56 8 13 6 42 10 93 
Belgium Ovarian Cancer Study Belgium BEL 1348 194 23 22 23 182 17 274 
Diseases of the Ovary and their Evaluation USA DOV 1119 293 18 84 29 235 136 515 
Diseases of the Ovary and their Evaluation       USA DVE 368 233 8 64 36 200 78 389 
Germany Ovarian Cancer Study Germany GER 413 95 21 21 6 68 59 189 
Hawaii Ovarian Cancer Study USA HAW 156 38 3 12 5 36 2 60 
Hannover-Jena Ovarian Cancer Study Germany HJO 273 140 9 26 4 107 116 266 
Hannover-Minsk Ovarian Cancer Study Germany HMO 138 50 7 12 1 1 121 142 
Helsinki Ovarian Cancer Study Finland HOC 447 113 45 28 13 0 135 221 
Hormones and Ovarian Cancer Prediction USA HOP 1464 377 30 84 42 333 145 654 
Danish Malignant Ovarian Tumor Study Denmark MAL 828 272 42 54 33 183 53 440 
Mayo Clinic Ovarian Cancer Case Control Study USA MAY 10 9 0 1 0 9 0 10 
Melbourne Collaborative Cohort Study Australia MCC 65 34 7 7 6 19 21 63 
MD Anderson Ovarian Cancer Study USA MDA 384 190 27 28 4 135 179 373 
Memorial Sloan Kettering Cancer Center USA MSK 593 382 0 20 18 343 73 467 
North Carolina Ovarian Cancer Study USA NCO 172 147 18 35 24 132 50 269 
New England Case-Control Study USA NEC 979 371 41 140 33 331 60 634 
Nurses' Health Study I and II USA NHS 425 68 7 14 6 0 100 127 
New Jersey Ovarian Cancer Study USA NJO 180 100 7 27 20 80 27 169 
University of Bergen, Haukeland University Hospital, 
Norway 
Norway NOR 370 135 15 27 11 85 87 237 
Nijmegen Ovarian Cancer Study Netherlands NTH 323 116 33 64 20 64 52 255 
Ovarian Cancer in Alberta and British Columbia Canada OVA 748 344 26 103 57 0 445 631 
Polish Ovarian Cancer Study Poland POC 417 199 33 39 9 0 341 422 
Polish Ovarian cancer Case Control Study (NCI) Poland POL 186 21 4 10 2 15 11 42 
UK Studies of Epidemiology and Risk Factors in Cancer 
Heredity (SEARCH) Ovarian Cancer Study 
UK SEA 1196 162 38 24 28 104 71 271 
UK Studies of Epidemiology and Risk Factors in Cancer 
Heredity (SEARCH) Ovarian Cancer Study 
UK SEB 4826 11 5 5 0 4 15 29 
Southampton Ovarian Cancer Study UK SOC 0 102 33 62 11 72 79 267 
Family Registry for Ovarian Cancer AND Genetic 
Epidemiology of Ovarian Cancer 
USA STA 313 154 16 32 20 135 35 251 
Familial Ovarian Tumor Study Canada TOR 74 8 1 7 2 0 11 21 
UC Irvine Ovarian Cancer Study USA UCI 367 166 19 48 23 143 32 277 
UK Ovarian Cancer Population Study UK UKO 1103 117 24 32 25 93 51 236 
Los Angeles County Case-Control Studies of Ovarian 
Cancer 
USA USC 1047 447 44 79 35 341 161 689 
Warsaw Ovarian Cancer Study Poland WOC 203 132 8 20 17 131 25 202 
 Total*   
 
21654 5828 662 1350 621 4121 2948 10065 
Supplementary Table 1. Description of individual OCAC studies and case‐control sample size. *Numbers differ from Table 1 in main manuscript, as these 
ones reflect the total number before Identity by descent (IBD) <0.10 filtering.
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Supplementary Figure 2. Contribution to the heritability by chromosome versus expected. Confidence intervals [0.05,0.95] 
were approximated through jackknifing up to 1000 times 
 
 
 
 
